Drug Discovery Weekly — April 6, 2026

FDA & Regulatory Decisions

1. FDA Shifts to Single-Trial Requirement for New Drug Approvals

In a significant regulatory policy change, FDA officials Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH, published a commentary detailing a new system under which the agency will require only one adequate and well-controlled study — rather than the traditional two — to approve certain new drugs. The policy is expected to accelerate development timelines considerably, though it raises questions about evidentiary standards and downstream supply chain planning. The shift represents one of the most consequential regulatory pivots in recent memory, potentially compressing the time-to-approval window for therapies targeting serious conditions.

2. Q2 2026 FDA Decision Calendar: Six Key Reviews in Queue

Six FDA decisions are expected in Q2 2026, listed chronologically by PDUFA date. The pipeline includes treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity — spanning multiple therapeutic areas and signalling a busy quarter for regulatory watchers.

3. FDA National Priority Voucher Pilot Program — Second Approval Granted

The FDA granted its second approval under the National Priority Voucher (CNPV) Pilot Program, which seeks to expedite applications addressing critical national health priorities, including innovative therapies, large unmet medical needs, domestic manufacturing, and affordability. The approved drug, Hernexeos, previously received both Breakthrough Therapy and Priority Review designations under the program.

Clinical Trial Spotlight

1. Capricor Therapeutics — Positive Phase 3 HOPE-3 Results for Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics announced positive topline results from the pivotal Phase 3 HOPE-3 study (n=106) of deramiocel in Duchenne Muscular Dystrophy (DMD). The randomized, double-blind, placebo-controlled trial met its primary endpoint — Performance of Upper Limb version 2.0 (PUL v2.0) — achieving statistical significance (p=0.03). Critically, the trial also hit its key secondary cardiac endpoint, left ventricular ejection fraction (LVEF), with statistical significance (p=0.04). The dual achievement — functional and cardiac improvement — is particularly meaningful in DMD, where cardiomyopathy is a leading cause of death. These results support a potential regulatory submission for deramiocel.

2. AstraZeneca — Tozorakimab Meets Primary Endpoint in Both OBERON and TITANIA Phase 3 COPD Trials

AstraZeneca reported that tozorakimab, its first-in-class IL-33 inhibitor, met the primary endpoint in both the OBERON and TITANIA Phase 3 trials in patients with COPD. Tozorakimab is a potent human immunoglobulin monoclonal antibody that uniquely inhibits IL-33 signalling in two ways, suppressing inflammation and disrupting the cycle of mucus dysfunction. Key secondary endpoints — including annualised rate of moderate-to-severe COPD exacerbations in the overall population of former and current smokers — are still being assessed, with full results expected in H1 2026. COPD affects hundreds of millions globally, and a validated IL-33 inhibitor could represent a meaningful new treatment option.

3. Karyopharm — Phase 3 SENTRY Trial in Myelofibrosis Meets First Co-Primary Endpoint

Karyopharm Therapeutics reported that its Phase 3 SENTRY trial in myelofibrosis met the first co-primary endpoint, demonstrating statistically significant improvement in spleen volume reduction. However, across other secondary and exploratory endpoints — including progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement — no meaningful difference was observed between the treatment and placebo arms. The mixed readout complicates the drug's regulatory path and raises questions about the overall clinical benefit profile that will need to be addressed in any regulatory submission.

Deals & Pipeline Moves

1. Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences (NASDAQ: NBIX) agreed to acquire Soleno Therapeutics (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion. The deal brings Soleno's rare disease franchise — centred on Prader-Willi syndrome — into Neurocrine's growing portfolio. The acquisition underscores the continued appetite for rare disease assets and Neurocrine's ambition to diversify beyond its CNS stronghold. The deal was announced earlier today.

2. Lilly's $6.3 Billion Centessa Bid Highlights CVR Trend in Biopharma M&A

In a notable structural development, both Biogen's recently announced $5.6 billion acquisition of Apellis Pharmaceuticals and Eli Lilly's $6.3 billion bid for Centessa Pharmaceuticals employ Contingent Value Rights (CVRs) — a voucher-like security that has seen renewed interest as a mechanism for bridging valuation gaps between buyers and sellers. This trend signals growing sophistication in deal structuring as acquirers seek to manage risk on late-stage pipeline assets. The M&A tracker at BioPharma Dive documents both transactions as part of an accelerating 2026 dealmaking environment.

Analysis: Development of the Week

FDA's Single-Trial Pivot: A Paradigm Shift or a Calculated Risk?

The FDA's announcement that it will accept single adequate and well-controlled studies as the basis for some new drug approvals is this week's most consequential development — and its implications extend far beyond regulatory procedure.

Why it matters for the field: The traditional two-trial standard has been a cornerstone of FDA evidentiary requirements for decades. Its logic was sound: replication reduces the probability of false positives, protects patients from ineffective or unsafe therapies, and builds a robust body of evidence. The new policy, authored by FDA officials Vinay Prasad and Martin Makary, signals a philosophical shift toward accepting mechanistically compelling evidence with a single well-powered study, particularly where unmet need is high and the biological rationale is strong.

For drug developers, this could translate to meaningful cost and time savings. A large Phase 3 trial can cost upward of $300–500 million. Eliminating the requirement for a confirmatory trial — even selectively — could accelerate timelines by two to four years for qualifying programs.

Competitive landscape implications: Companies with single pivotal trials currently in progress may now have a clearer regulatory pathway. Rare disease developers — who often struggle to enroll large enough populations for duplicate trials — stand to benefit most. The policy may also shift competitive dynamics in larger indications if sponsors can deploy capital previously earmarked for confirmatory studies toward pipeline expansion.

Patient impact: For patients with serious or life-threatening conditions where no approved options exist, faster access to novel therapies is an unambiguous benefit. However, the medical community will need to monitor post-marketing data carefully, as the single-trial standard inherently accepts greater residual uncertainty about a drug's effect size and generalizability.

The open question: The policy change raises a longer-term concern about downstream supply chain planning, as manufacturers typically calibrate production capacity based on approval timelines. A compressed approval window could create commercial readiness challenges — particularly for biologics with complex manufacturing processes.

The FDA's new direction reflects its broader mandate under the current leadership to modernize regulatory science, reduce bureaucratic burden, and put patients first. Whether this balance is struck correctly will only be known in retrospect — but the industry will be watching closely.

What to Watch

1. AstraZeneca Tozorakimab Full Phase 3 Data (H1 2026): Both the OBERON and TITANIA trials met their primary endpoints, but the full secondary endpoint data — particularly annualised exacerbation rates — are expected in the first half of 2026. Complete results will determine whether tozorakimab can mount a regulatory submission for COPD.

2. Karyopharm SENTRY Trial — Second Co-Primary Endpoint Readout: The SENTRY myelofibrosis trial met its first co-primary endpoint (spleen volume reduction) but missed on key secondary endpoints. The second co-primary endpoint — symptom response — is anticipated and will be decisive for Karyopharm's regulatory strategy.

3. Q2 2026 PDUFA Dates: The FDA calendar is full, with decisions expected on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, haematological malignancies, HIV-1, and obesity. Watch for the first Q2 approvals in coming weeks.

4. Neurocrine/Soleno Integration Update: Following the $2.9 billion acquisition announcement, watch for deal closing timelines and any regulatory filings related to Soleno's Prader-Willi syndrome candidate as it moves under Neurocrine's commercial infrastructure.

5. FDA Single-Trial Policy — First Application Cases: Industry and regulatory analysts will be watching closely for the first instances of sponsors formally invoking the new single-trial standard in IND or NDA discussions. How the FDA operationalises the policy will matter as much as the policy itself.